Recently, the core R&D team from Guangzhou Anxin Pharmaceutical Co., Ltd. visited the Pharmaceutical Alkali Factory Co., Ltd. for an on-site tour and discussion. The company's leadership team, along with project managers and technical personnel from R&D, registration, and production departments, participated in the meeting.

During the discussion, both parties conducted in-depth exchanges on key operational details including the industrialization advancement of global narcotic and psychotropic drug projects, quality standards, registration applications, and supply chain assurance. They communicated item by item on core aspects such as process routes, batch trial production plans, quality standard coordination, impurity profile research, joint review of application materials, sample delivery schedules, and supply chain production scheduling, fully exchanging views. The two sides explored a proposed plan for subsequent joint technical research and agreed to establish a regular communication mechanism to collaboratively resolve technical and registration issues during the development process.

This face-to-face in-depth exchange effectively broke down information barriers between upstream and downstream, further enhanced understanding of national narcotic and psychotropic drug market information, clarified the company's positioning in the global narcotic and psychotropic drug market, and opened up new ideas and directions for future development.

Prior to the discussion, the visiting team toured the Pharmaceutical Alkali Factory's R&D laboratory, quality testing center, and raw material workshop, gaining a detailed understanding of the full-process control capabilities including raw material drug synthesis process development, impurity control systems, GMP quality management, and sample stability research. On-site technical personnel introduced the process progress, purification strategies, and scale-up experience of related narcotic raw material drugs, and provided detailed briefings on the project's current R&D progress, technical difficulties, and risk control points.

Guangzhou Anxin Pharmaceutical fully affirmed the Pharmaceutical Alkali Factory's R&D strength and compliance system in the field of raw material drugs. Going forward, both parties will follow the consensus reached in this discussion, leverage their respective advantages in raw material drug R&D and market transformation, strengthen cooperation and exchange, reinforce research and feasibility studies, and actively seek entry points for collaboration to provide stable, high-quality raw material drug supplies for clinical use.